Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Assets (2016 - 2025)

Historic Assets for Bio-Techne (TECH) over the last 16 years, with Q4 2025 value amounting to $2.5 billion.

  • Bio-Techne's Assets fell 553.19% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year decrease of 553.19%. This contributed to the annual value of $2.6 billion for FY2025, which is 539.96% down from last year.
  • As of Q4 2025, Bio-Techne's Assets stood at $2.5 billion, which was down 553.19% from $2.5 billion recorded in Q3 2025.
  • Bio-Techne's Assets' 5-year high stood at $2.8 billion during Q3 2023, with a 5-year trough of $2.1 billion in Q1 2021.
  • Moreover, its 5-year median value for Assets was $2.5 billion (2025), whereas its average is $2.5 billion.
  • As far as peak fluctuations go, Bio-Techne's Assets surged by 1721.34% in 2023, and later crashed by 767.06% in 2025.
  • Over the past 5 years, Bio-Techne's Assets (Quarter) stood at $2.3 billion in 2021, then rose by 2.54% to $2.4 billion in 2022, then rose by 15.54% to $2.7 billion in 2023, then dropped by 2.21% to $2.7 billion in 2024, then dropped by 5.53% to $2.5 billion in 2025.
  • Its Assets was $2.5 billion in Q4 2025, compared to $2.5 billion in Q3 2025 and $2.6 billion in Q2 2025.